Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Frances R. Balkwill, Anil K. Sood et al.|Nature reviews. Cancer|2011Cited by 1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D.L. Bowtell, Frances R. Balkwill, Hani Gabra et al.|Nature reviews. Cancer|2015Cited by 1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseNicoletta Colombo, Cristiana Sessa, Andreas du Bois et al.|Annals of Oncology|2019Cited by 1.2k
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJonathan A. Ledermann, Anna Fagotti, Xavier Matías‐Guiu et al.|Annals of Oncology|2024Cited by 277
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet|2019Cited by 223